Viking Therapeutics, Inc.
VKTX · Healthcare
$33.67
Cargando gráfico…
Noticias
Últimos titulares de esta acción
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
Viking Therapeutics (VKTX) gained 1.43% in the latest session, outperforming the S&P 500's 1.06% gain. However, the stock has depreciated 0.03% over the past month, underperforming the Medical sector's 5.75% gain. The company is expected to report an EPS of -$1 (down 23.46% YoY) with full-year consensus estimates of -$4.47 EPS and $0 million revenue. VKTX holds a Zacks Rank #3 (Hold) rating, while its industry (Medical - Biomedical and Genetics) ranks in the bottom 34% of all industries.
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong
While three Wall Street analysts have bullish $100 price targets on Viking Therapeutics (implying a tripling), the author argues this is overly optimistic. Viking's weight-loss drug VK2735 would need near-flawless phase 3 data showing 23-26% mean weight loss to justify such gains, and any clinical setback could sink the stock. The author recommends only risk-tolerant investors consider a small position.
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Keros Therapeutics reported a Q2 2026 loss of $1.45 per share, missing consensus estimates, with revenues falling to zero from $18.2 million year-over-year. The company has no marketed products and is focusing on pipeline development. With $257.6 million in cash, the company expects runway into H1 2028. The stock received a Zacks Rank #3 (Hold) rating with an F VGM Score.
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?
Viking Therapeutics has sufficient cash reserves ($502M) to fund operations through 2028, with a key near-term catalyst in Q3 2026 when phase 1 maintenance trial data for its lead drug VK2735 will be released. This data could significantly impact investor sentiment regarding the company's dual-formulation strategy (subcutaneous injection followed by oral maintenance), though it's unlikely to derail the ongoing phase 3 trials. The trial results will inform dosing decisions for upcoming extension studies.
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
Eli Lilly and Viking Therapeutics are competing in the rapidly growing GLP-1 drug market. Eli Lilly leads with approved products like tirzepatide generating strong revenue ($9.9B for Mounjaro, $4.9B for Zepbound in Q2), while Viking Therapeutics is a clinical-stage biotech with promising VK2735 candidate showing strong phase 2 results. The article recommends Eli Lilly as the safer choice due to its established portfolio and limited downside risk, though Viking Therapeutics offers higher upside potential if its phase 3 trials succeed.